Format
Sort by
Items per page

Send to

Choose Destination

Best matches for "Risperidone":

Search results

Items: 1 to 20 of 9671

1.

Elucidating the Mechanism(s) Underlying Antipsychotic and Antidepressant-Mediated Fractures.

Houseknecht KL, Bouchard CC, Black CA.

J Ment Health Clin Psychol. 2017;1(1):9-13. doi: 10.29245/2578-2959/2018/1.1106. Epub 2017 Dec 26.

2.

Pharmacological Prevention of Postoperative Delirium: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Liu Y, Li XJ, Liang Y, Kang Y.

Evid Based Complement Alternat Med. 2019 Mar 14;2019:9607129. doi: 10.1155/2019/9607129. eCollection 2019. Review.

3.

Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.

Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M.

Lancet Psychiatry. 2019 May;6(5):418-426. doi: 10.1016/S2215-0366(19)30088-4. Epub 2019 Apr 15.

PMID:
31000417
4.

CYP2D6 testing to guide risperidone and aripiprazole therapy.

Bousman CA.

Lancet Psychiatry. 2019 May;6(5):362-364. doi: 10.1016/S2215-0366(19)30138-5. Epub 2019 Apr 15. No abstract available.

PMID:
31000416
5.

Blonanserin ameliorates social deficit through dopamine-D3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia.

Takeuchi S, Hida H, Uchida M, Naruse R, Yoshimi A, Kitagaki S, Ozaki N, Noda Y.

Neurochem Int. 2019 Apr 15. pii: S0197-0186(19)30111-1. doi: 10.1016/j.neuint.2019.04.008. [Epub ahead of print]

PMID:
30998952
6.

Distinct Dopamine D₂ Receptor Antagonists Differentially Impact D₂ Receptor Oligomerization.

Wouters E, Marín AR, Dalton JAR, Giraldo J, Stove C.

Int J Mol Sci. 2019 Apr 4;20(7). pii: E1686. doi: 10.3390/ijms20071686.

7.

The effect of treatment response on endothelial function and arterial stiffness in depression. A prospective study.

Kokras N, Papadopoulou E, Georgiopoulos G, Dalla C, Petropoulos I, Kontogiannis C, Laina A, Bampatsias D, Stellos K, Kouzoupis AV, Stamatelopoulos K.

J Affect Disord. 2019 Apr 9;252:190-200. doi: 10.1016/j.jad.2019.04.024. [Epub ahead of print]

PMID:
30986734
8.

Paliperidone extended-release in the short- and long-term treatment of schizophrenia.

Valsecchi P, Garozzo A, Nibbio G, Barlati S, Deste G, Turrina C, Sacchetti E, Vita A.

Riv Psichiatr. 2019 Mar-Apr;54(2):43-58. doi: 10.1708/3142.31245.

PMID:
30985829
9.

Neuroprotective effects of the second generation antipsychotics.

Chen AT, Nasrallah HA.

Schizophr Res. 2019 Apr 11. pii: S0920-9964(19)30134-3. doi: 10.1016/j.schres.2019.04.009. [Epub ahead of print] Review.

PMID:
30982644
10.

Oral and Dental Findings in Emanuel Syndrome.

Puranik CP, Katechia B.

Int J Paediatr Dent. 2019 Apr 13. doi: 10.1111/ipd.12502. [Epub ahead of print]

PMID:
30980693
11.

Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial.

Mahdavinasab SM, Saghazadeh A, Motamed-Gorji N, Vaseghi S, Mohammadi MR, Alichani R, Akhondzadeh S.

Eur Child Adolesc Psychiatry. 2019 Apr 12. doi: 10.1007/s00787-019-01333-5. [Epub ahead of print]

PMID:
30980177
12.

A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia.

Osmanova DZ, Freidin MB, Fedorenko OY, Pozhidaev IV, Boiko AS, Vyalova NM, Tiguntsev VV, Kornetova EG, Loonen AJM, Semke AV, Wilffert B, Bokhan NA, Ivanova SA.

BMC Med Genet. 2019 Apr 9;20(Suppl 1):47. doi: 10.1186/s12881-019-0773-3.

13.

Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review.

Keramatian K, Chakrabarty T, Yatham LN.

CNS Drugs. 2019 Apr 8. doi: 10.1007/s40263-019-00629-z. [Epub ahead of print]

PMID:
30963507
14.

Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report database: association of evelolimus use with diabetes.

Konishi H, Shirakawa J, Arai M, Terauchi Y.

Endocr J. 2019 Apr 2. doi: 10.1507/endocrj.EJ18-0553. [Epub ahead of print]

15.

Benzodiazepines and/or neuroleptics for the treatment of delirium in palliative care?-a critical appraisal of recent randomized controlled trials.

Gaertner J, Eychmueller S, Leyhe T, Bueche D, Savaskan E, Schlögl M.

Ann Palliat Med. 2019 Mar 26. pii: apm.2019.03.06. doi: 10.21037/apm.2019.03.06. [Epub ahead of print]

16.

Systematic Review of Gender Bias in the Clinical Trials of New Long-Acting Antipsychotic Drugs.

Santos-Casado M, García-Avello A.

J Clin Psychopharmacol. 2019 May/Jun;39(3):264-272. doi: 10.1097/JCP.0000000000001041.

PMID:
30939594
17.

Shared Obsessive-Compulsive Disorder: An Italian Case Report.

Benatti B, Arici C, Altamura AC, DellʼOsso B.

J Nerv Ment Dis. 2019 Apr;207(4):311-313. doi: 10.1097/NMD.0000000000000967.

PMID:
30920479
18.

Adverse Events Associated with Risperidone Use in Pediatric Patients: A Retrospective Biobank Study.

Oshikoya KA, Carroll R, Aka I, Roden DM, Van Driest SL.

Drugs Real World Outcomes. 2019 Mar 27. doi: 10.1007/s40801-019-0151-7. [Epub ahead of print]

PMID:
30919267
19.

Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting.

Scherf-Clavel M, Weidner A, Deckert J, Menke A, Unterecker S.

Pharmacopsychiatry. 2019 Mar 26. doi: 10.1055/a-0869-8053. [Epub ahead of print]

PMID:
30913567
20.

Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial.

Higuchi T, Iyo M, Kwon JS, Chou YH, Chen HK, Chen JY, Chen TT, Huang SY, Lee JS, Saeki Y, Tanaka H, Wang TS, Wu BJ, Katoh T, Ishigouoka J.

Asia Pac Psychiatry. 2019 Mar 25:e12354. doi: 10.1111/appy.12354. [Epub ahead of print]

PMID:
30912222

Supplemental Content

Loading ...
Support Center